-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Xenon Pharmaceuticals Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2020 to Q3 2025.
- Xenon Pharmaceuticals Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $6.12M, a 42.1% decline year-over-year.
- Xenon Pharmaceuticals Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $31.1M, a 25.4% decline year-over-year.
- Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2024 was $40.9M, a 30.3% increase from 2023.
- Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2023 was $31.4M, a 707% increase from 2022.
- Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2022 was $3.89M, a 3603% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)